Fever of unknown origin, a rare presentation of metastatic prostate cancer: Case report

We report one case, in which the patient presented to the emergency department with lower urinary tract symptoms, fever and consumptive syndrome. Acute prostatitis was initially suspected, but subsequently prostate adenocarcinoma was diagnosed.This case enables us to consider the possibility of prostate adenocarcinoma as the diagnose in patients with fever of unknown origin, and the role of procalcitonin to rule out the presence of infection.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research

Related Links:

Transient acantholytic dermatosis (TAD) is a relatively common entity that has been also noted to occur in patients with cancer. Herein, we describe a case of transient acantholytic dermatosis occurring in a patient with a history of prostate cancer status post radiation, now being treated with combination therapy with pembrolizumab and carboplatin-pemetrexed for advanced lung adenocarcinoma. Our case emphasizes the importance of being cognizant of TAD and its associations, particularly in cancer patients.
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
Purpose: To perform a multi-institutional analysis of patients with synchronous prostate and rectosigmoid cancers.Materials and Methods: A retrospective review of Duke University and Durham Veterans Affairs Medical Center records was performed for men with both prostate and rectosigmoid adenocarcinomas from 1988 to 2017. Synchronous presentation was defined as symptoms, diagnosis, or treatment of both cancers within 12 months of each other. The primary study endpoint was overall survival. Univariate and multivariable Cox regression was performed.Results: Among 31,883 men with prostate cancer, 330 (1%) also had rectosigmoid...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
MONDAY, March 23, 2020 -- For men with intermediate- and high-risk prostate adenocarcinoma, 10-year outcomes are similar with conventionally fractionated intensity-modulated radiation therapy (C-IMRT) or moderate hypofractionated IMRT (H-IMRT),...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Contributors : Ivana Hermanova ; Patricia Z úñiga-García ; Sonia Fernandez-Ruiz ; Arkaitz Carracedo ; Cristian Suárez-Cabrera ; Iris Lodewijk ; Jesús M ParamioSeries Type : Expression profiling by arrayOrganism : Mus musculusIn order to identify the contribution of Lkb1 loss to Pten driven prostate cancer progression, we engineered a prostate conditional mutant mice in which was induced the loss of Lkb1 in combination with heterozygous loss of the prostate tumor suppressor Pten (Ptenpc+/- Lkb1pc-/-). This mouse model developed metastatic prostate squamous cell carcinoma. We compared this ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
CONCLUSIONS: Our results highlight that ADT with or without Cy/GVAX induces a complex immune response within the prostate tumor microenvironment. These data have important implications for combining ADT with immunotherapy. In particular, our finding that ADT increases both CD8+ T cells and Tregs, supports the development of regimens combining ADT with Treg-depleting agents in the treatment of prostate cancer. PMID: 32173650 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
We report a case of a 59-year-old man with prostate adenocarcinoma, Gleason score 9 after prostatectomy and adjuvant radiotherapy. The patient showed biochemical recurrence. On standard 68Ga-PSMA PET/CT examination, 60 minutes postinjection, the PET/CT images showed only trace accumulation in the ureters. To identify lesions close to the ureters, imaging of the pelvis was performed 2 hours postinjection. The delayed image showed clearly visible increased uptake in a right internal iliac lymph node that was normal-sized by CT. The patient underwent radiotherapy with planning based on the 68Ga-PSMA PET/CT image. Follow-up te...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
in CM Abstract Lineage plasticity, the ability of cells to transition from one committed developmental pathway to another, has been proposed as a source of intratumoural heterogeneity and of tumour adaptation to an adverse tumour microenvironment including exposure to targeted anticancer treatments. Tumour cell conversion into a different histological subtype has been associated with a loss of dependency on the original oncogenic driver, leading to therapeutic resistance. A well-known pathway of lineage plasticity in cancer - the histological transformation of adenocarcinomas to aggressive neuroendocrine derivativ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research
This study aimed to first elucidate prostate-specific antigen (PSA) kinetics in prostate cancer patients treated with carbon ion radiotherapy (CIRT). From 2010 to 2015, 131 patients with prostate adenocarcinoma treated with CIRT (57.6 Gy relative biological effectiveness (RBE) in 16 fractions) alone were recruited. PSA was measured at 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 months post-CIRT. PSA bounce was defined as PSA increase over a cutoff followed by spontaneous decrease to or below the pre-bounce nadir. PSA failure was determined using the Phoenix criteria (nadir + 2.0 ng/mL). As a result, non-f...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, "knowing what is growing" will hel...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Reviews Source Type: research
Condition:   Prostate Adenocarcinoma Intervention:   Drug: Niraparib Pill Sponsor:   Abramson Cancer Center of the University of Pennsylvania Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Emergency Medicine | Prostate Cancer | Urology & Nephrology